NCT06427954 Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
| NCT ID | NCT06427954 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-08-06 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2024-08-06 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multi-site randomized trial of the THRIVE digital health application versus usual care to evaluate the effect of THRIVE on quality of life (QOL), physical and psychological symptoms, coping, and self-efficacy in 250 patients with newly diagnosed advanced lung cancer.
Eligibility Criteria
Inclusion Criteria: * Adults (greater than or equal to 18 years) * Diagnosed with advanced non-small cell lung cancer (NSCLC) that is not being treated with curative intent or extensive stage small cell lung cancer (SCLC) within the past 12 weeks. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 0-2 (i.e., fully active to at least ambulatory and up and about more than 50% of waking hours). * Sufficient English proficiency to utilize THRIVE in English (Note: patients can complete outcome measures in Spanish if preferred). Exclusion Criteria: * Significant uncontrolled psychiatric disorder (e.g., psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the ability to participate in study procedures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06427954 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06427954 currently recruiting?
Yes, NCT06427954 is actively recruiting participants. Contact the research team at jtemel@partners.org for enrollment information.
Where is the NCT06427954 trial being conducted?
This trial is being conducted at Los Angeles, United States, Los Angeles, United States, Boston, United States.
Who is sponsoring the NCT06427954 clinical trial?
NCT06427954 is sponsored by Massachusetts General Hospital. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.